GraniteShares Announces Weekly Distributions for its YieldBOOST ETFs: COYY, TSYY, NVYY, XBTY, AMYY, TQQY, AZYY, YSPY, MTYY, PLYY, HOYY, SMYY, BBYY, FBYY, IOYY, MAAY, NUGY, SEMY, QBY, RGYY, HMYY and RTYY GlobeNewswire January 08, 2026 New York, Jan. 08, 2026 (GLOBE NEWSWIRE) — GraniteShares today announced the weekly distributions for its GraniteShares YieldBOOST ETFs: COYY, […]

NeurAxis Achieves Major Milestone with AMA Category I CPT(R) Code Now in Effect, Establishing a Permanent Reimbursement Pathway GlobeNewswire January 08, 2026 The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization. The assignment of a Category I CPT(R) code demonstrates a strong message to payers, both commercial

King Copper Discovery Announces Private Placement GlobeNewswire January 08, 2026 VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — King Copper Discovery Corp. (“King Copper“, or the “Company“; KCP-TSXV, TBXXF-OTCQB, 3RI0-FSE) is proposing to complete a non-brokered private placement financing of 25 million units at a price of 60 cents per unit for gross proceeds

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib GlobeNewswire January 08, 2026 Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy First Breakthrough Therapy Designation for an investigational

Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes GlobeNewswire January 08, 2026 PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer,

Kepler Fusion Technologies Unveils New CEO Interview Highlighting Progress and Vision for Its Proprietary Fusion Power Platform GlobeNewswire January 08, 2026 Fusion platform positioned for military, commercial, residential, and remote deployments via power purchase agreements. SOUTHLAKE, Texas, Jan. 08, 2026 (GLOBE NEWSWIRE) — Renewal Fuels, Inc. (OTC: RNWF) (“RNWF” or the “Company”), together with Kepler

Vickery Energy Acquires Appalachia Gas Assets from Tribune Resources GlobeNewswire January 08, 2026 FORT WORTH, Texas, Jan. 08, 2026 (GLOBE NEWSWIRE) — Vickery Energy Partners, LLC (“Vickery”), a portfolio company of Quantum Capital Group, announced today that it has closed on the acquisition of Tribune Resources, LLC from Tribune Resources, Inc (“Tribune”). The transaction includes

Pentec Health Acquires Hartley Medical, Advancing Intrathecal Pain and Implanted Pump Management GlobeNewswire January 08, 2026 Boothwyn, PA., Jan. 08, 2026 (GLOBE NEWSWIRE) — Pentec Health, Inc. (Pentec) today announced the acquisition of Hartley Medical Center Pharmacy, LLC (Hartley Medical), a nationally recognized compounding pharmacy focused on the sterile compounding of intrathecal (IT) medications used

R1 Launches Phare Audit, the AI-Native Solution to Capture Full Reimbursement, Reduce Revenue Leakage and Improve Quality Phare Audit Uses Proprietary Agentic AI to Maximize Earned Reimbursement, Enhancing R1's Industry-Leading DRG-V with Full Auditability GlobeNewswire January 08, 2026 CHICAGO, Jan. 08, 2026 (GLOBE NEWSWIRE) — R1 (“R1” or the “Company”), the leader in healthcare revenue

Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials GlobeNewswire January 08, 2026 FDA Clears IND Allowing Phase 2a Trial of NAV-240 in Hidradenitis Suppurativa to Begin Dosing in Q1 2026 HREC Approval Received for Next-Generation Bispecific NAV-242 to Initiate First-in-Human Phase 1 Program with Ph1a